RLAY vs. BCRX, IMTX, MESO, RGNX, CRGX, AUTL, HLVX, KYTX, TARS, and NVAX
Should you be buying Relay Therapeutics stock or one of its competitors? The main competitors of Relay Therapeutics include BioCryst Pharmaceuticals (BCRX), Immatics (IMTX), Mesoblast (MESO), REGENXBIO (RGNX), CARGO Therapeutics (CRGX), Autolus Therapeutics (AUTL), HilleVax (HLVX), Kyverna Therapeutics (KYTX), Tarsus Pharmaceuticals (TARS), and Novavax (NVAX). These companies are all part of the "biological products, except diagnostic" industry.
BioCryst Pharmaceuticals (NASDAQ:BCRX) and Relay Therapeutics (NASDAQ:RLAY) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their community ranking, media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.
BioCryst Pharmaceuticals received 439 more outperform votes than Relay Therapeutics when rated by MarketBeat users. Likewise, 66.43% of users gave BioCryst Pharmaceuticals an outperform vote while only 60.32% of users gave Relay Therapeutics an outperform vote.
In the previous week, BioCryst Pharmaceuticals had 24 more articles in the media than Relay Therapeutics. MarketBeat recorded 40 mentions for BioCryst Pharmaceuticals and 16 mentions for Relay Therapeutics. BioCryst Pharmaceuticals' average media sentiment score of 0.63 beat Relay Therapeutics' score of 0.57 indicating that Relay Therapeutics is being referred to more favorably in the news media.
BioCryst Pharmaceuticals has a beta of 1.96, meaning that its stock price is 96% more volatile than the S&P 500. Comparatively, Relay Therapeutics has a beta of 1.68, meaning that its stock price is 68% more volatile than the S&P 500.
BioCryst Pharmaceuticals has higher revenue and earnings than Relay Therapeutics. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks.
BioCryst Pharmaceuticals presently has a consensus target price of $14.00, suggesting a potential upside of 174.51%. Relay Therapeutics has a consensus target price of $24.00, suggesting a potential upside of 268.66%. Given BioCryst Pharmaceuticals' higher possible upside, analysts clearly believe Relay Therapeutics is more favorable than BioCryst Pharmaceuticals.
BioCryst Pharmaceuticals has a net margin of -68.36% compared to BioCryst Pharmaceuticals' net margin of -1,263.49%. Relay Therapeutics' return on equity of 0.00% beat BioCryst Pharmaceuticals' return on equity.
85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are held by institutional investors. 4.4% of BioCryst Pharmaceuticals shares are held by company insiders. Comparatively, 4.3% of Relay Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
BioCryst Pharmaceuticals beats Relay Therapeutics on 12 of the 17 factors compared between the two stocks.
Get Relay Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for RLAY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RLAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Relay Therapeutics Competitors List
Related Companies and Tools
